Jacky Vonderscher

Company: ENYO Pharma

Job title: Co-Founder & Chief Executive Officer

Seminars:

Developing Vonafexor and analogs as strong antifibrotic and anti-inflammatory therapeutics currently in clinical stage for rare and common renal diseases like Alport syndrome and CKD 11:30 am

Phase 2 “ALPESTRIA-1” trial is ongoing as a PoC with Vonafexor in Alport syndrome (topline data – Q4-2025). PoC Phase 2 trial is ready to start with Vonafexor analog for grade 3 CKD patients having MASH to confirm the LIVIFY trial results. Validating the unique mechanism of action of Vonafexor and its analogs compared to…Read more

day: Day One Track 2 AM